Compounds and methods for treating central nervous system disorders
By using isolated peptides with amino acid sequence LRP, such as KKLRP and AKKLRP, the treatment challenges of central nervous system disorders, especially autism spectrum disorders and Alzheimer's disease, have been solved, and effective treatment results for these diseases have been achieved.
Patent Information
- Application Number
- CN202480066319.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-31
- Filing Date
- 2024-08-29
- Publication Date
- 2026-05-15
AI Technical Summary
Current technologies are insufficient to effectively treat central nervous system disorders, particularly autism spectrum disorders and Alzheimer's disease, and there is a lack of pharmacological treatment options for Ferenc McDermid syndrome.
A separate peptide comprising the amino acid sequence LRP or variants thereof, such as KKLRP and AKKLRP, is provided, which, by administration of these peptides or pharmaceutically acceptable combinations thereof, acts directly or indirectly on the central nervous system to treat central nervous system disorders such as autism spectrum disorder, Alzheimer's disease, etc.
These peptides significantly improve the symptoms of central nervous system disorders, enhance synaptic strength and neural function, regulate circadian rhythms, enhance IGF2R activity, and provide effective treatment for conditions such as autism spectrum disorder and Alzheimer's disease.